메뉴 건너뛰기




Volumn 7, Issue 9, 2015, Pages 5155-5168

Interferon-free hepatitis c treatment before and after liver transplantation: The role of HCV drug resistance

Author keywords

Antiviral therapy; Boceprevir; Daclatasvir; Dasabuvir; Direct acting antiviral; Hepatitis C; Interferon; Ledipasvir; Liver transplantation; Ombitasvir; Paritaprevir; Ribavirin; Simeprevir; Sofosbuvir; Telaprevir

Indexed keywords

BOCEPREVIR; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; DACLATASVIR; DASABUVIR; HEPACIVIRIN; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT; PROTEINASE INHIBITOR;

EID: 84942436324     PISSN: 19994915     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7092864     Document Type: Review
Times cited : (18)

References (69)
  • 1
    • 4544285158 scopus 로고    scopus 로고
    • Long-term results and modeling to predict outcomes in recipients with HCV infection: Results of the NIDDK liver transplantation database
    • Charlton, M.; Ruppert, K.; Belle, S.H.; Bass, N.; Schafer, D.; Wiesner, R.H.; Detre, K.; Wei, Y.; Everhart, J. Long-term results and modeling to predict outcomes in recipients with HCV infection: Results of the NIDDK liver transplantation database. Liver Transplant. 2004, 10, 1120–1130.
    • (2004) Liver Transplant , vol.10 , pp. 1120-1130
    • Charlton, M.1    Ruppert, K.2    Belle, S.H.3    Bass, N.4    Schafer, D.5    Wiesner, R.H.6    Detre, K.7    Wei, Y.8    Everhart, J.9
  • 3
    • 58849128803 scopus 로고    scopus 로고
    • The natural history of recurrent hepatitis C and what influences this
    • Gane, E.J. The natural history of recurrent hepatitis C and what influences this. Liver Transplant. 2008, 14 (Suppl. 2), S36–S44.
    • (2008) Liver Transplant , vol.14 , pp. S36-S44
    • Gane, E.J.1
  • 4
    • 0036207348 scopus 로고    scopus 로고
    • The association between hepatitis Cinfection and survival after orthotopic liver transplantation
    • Forman, L.M.; Lewis, J.D.; Berlin, J.A.; Feldman, H.I.; Lucey, M.R. The association between hepatitis Cinfection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122, 889–896.
    • (2002) Gastroenterology , vol.122 , pp. 889-896
    • Forman, L.M.1    Lewis, J.D.2    Berlin, J.A.3    Feldman, H.I.4    Lucey, M.R.5
  • 7
    • 84876296995 scopus 로고    scopus 로고
    • Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment
    • Berenguer, M.; Schuppan, D. Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment. J. Hepatol. 2013, 58, 1028–1041.
    • (2013) J. Hepatol , vol.58 , pp. 1028-1041
    • Berenguer, M.1    Schuppan, D.2
  • 10
    • 78751505015 scopus 로고    scopus 로고
    • Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection
    • Charlton, M.R.; Thompson, A.; Veldt, B.J.; Watt, K.; Tillmann, H.; Poterucha, J.J.; Heimbach, J.K.; Goldstein, D.; McHutchison, J. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011, 53, 317–324.
    • (2011) Hepatology , vol.53 , pp. 317-324
    • Charlton, M.R.1    Thompson, A.2    Veldt, B.J.3    Watt, K.4    Tillmann, H.5    Poterucha, J.J.6    Heimbach, J.K.7    Goldstein, D.8    McHutchison, J.9
  • 11
    • 78049470128 scopus 로고    scopus 로고
    • Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C
    • 1585.e1–1585.e3
    • Fukuhara, T.; Taketomi, A.; Motomura, T.; Okano, S.; Ninomiya, A.; Abe, T.; Uchiyama, H.; Soejima, Y.; Shirabe, K.; Matsuura, Y.; et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010, 139, 1577–1585, 1585.e1–1585.e3.
    • (2010) Gastroenterology , vol.139 , pp. 1577-1585
    • Fukuhara, T.1    Taketomi, A.2    Motomura, T.3    Okano, S.4    Ninomiya, A.5    Abe, T.6    Uchiyama, H.7    Soejima, Y.8    Shirabe, K.9    Matsuura, Y.10
  • 12
    • 0242456078 scopus 로고    scopus 로고
    • Host and donor risk factors before and after liver transplantation that impact HCV recurrence
    • Berenguer, M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transplant. 2003, 9, S44–S47.
    • (2003) Liver Transplant , vol.9 , pp. S44-S47
    • Berenguer, M.1
  • 13
    • 84885308430 scopus 로고    scopus 로고
    • Drug-drug interactions during antiviral therapy for chronic hepatitis C
    • Kiser, J.J.; Burton, J.R., Jr.; Everson, G.T. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 596–606.
    • (2013) Nat. Rev. Gastroenterol. Hepatol , vol.10 , pp. 596-606
    • Kiser, J.J.1    Burton, J.R.2    Everson, G.T.3
  • 14
    • 22844435314 scopus 로고    scopus 로고
    • Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.
    • Bizollon, T.; Pradat, P.; Mabrut, J.Y.; Chevallier, M.; Adham, M.; Radenne, S.; Souquet, J.C.; Ducerf, C.; Baulieux, J.; Zoulim, F.; et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am. J. Transplant. 2005, 5, 1909–1913.
    • (2005) Am. J. Transplant. , vol.5 , pp. 1909-1913
    • Bizollon, T.1    Pradat, P.2    Mabrut, J.Y.3    Chevallier, M.4    Adham, M.5    Radenne, S.6    Souquet, J.C.7    Ducerf, C.8    Baulieux, J.9    Zoulim, F.10
  • 15
    • 46349089961 scopus 로고    scopus 로고
    • Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin
    • Berenguer, M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J. Hepatol. 2008, 49, 274–287.
    • (2008) J. Hepatol , vol.49 , pp. 274-287
    • Berenguer, M.1
  • 19
    • 84913529500 scopus 로고    scopus 로고
    • P1185 Interim SVR 12 results from the Telaprevir phase 3B REPLACE study in treatment-naive stable liver transplant patients with genotype 1 HCV infection
    • Forns, X.; Samuel, D.; Mutimer, D.; Fagiouli, M.; Navasa, M. P1185 Interim SVR 12 results from the Telaprevir phase 3B REPLACE study in treatment-naive stable liver transplant patients with genotype 1 HCV infection. J. Hepatol. 2014, 60 (Suppl. 1).
    • (2014) J. Hepatol , vol.60
    • Forns, X.1    Samuel, D.2    Mutimer, D.3    Fagiouli, M.4    Navasa, M.5
  • 21
    • 84904647749 scopus 로고    scopus 로고
    • ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection
    • Andreone, P.; Colombo, M.G.; Enejosa, J.V.; Koksal, I.; Ferenci, P.; Maieron, A.; Mullhaupt, B.; Horsmans, Y.; Weiland, O.; Reesink, H.W.; et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014, 147, 359.e351–365.e351.
    • (2014) Gastroenterology , vol.147 , pp. e351-e365
    • Andreone, P.1    Colombo, M.G.2    Enejosa, J.V.3    Koksal, I.4    Ferenci, P.5    Maieron, A.6    Mullhaupt, B.7    Horsmans, Y.8    Weiland, O.9    Reesink, H.W.10
  • 30
    • 84929582082 scopus 로고    scopus 로고
    • Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant
    • Pungpapong, S.; Aqel, B.; Leise, M.; Werner, K.T.; Murphy, J.L.; Henry, T.M.; Ryland, K.; Chervenak, A.E.; Watt, K.D.; Vargas, H.E.; et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015, 61, 1880–1886.
    • (2015) Hepatology , vol.61 , pp. 1880-1886
    • Pungpapong, S.1    Aqel, B.2    Leise, M.3    Werner, K.T.4    Murphy, J.L.5    Henry, T.M.6    Ryland, K.7    Chervenak, A.E.8    Watt, K.D.9    Vargas, H.E.10
  • 31
    • 84940582565 scopus 로고    scopus 로고
    • Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
    • Yoshimi, S.; Imamura, M.; Murakami, E.; Hiraga, N.; Tsuge, M.; Kawakami, Y.; Aikata, H.; Abe, H.; Hayes, C.N.; Sasaki, T.; et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J. Med. Virol. 2015, 87, 1913–1920.
    • (2015) J. Med. Virol. , vol.87 , pp. 1913-1920
    • Yoshimi, S.1    Imamura, M.2    Murakami, E.3    Hiraga, N.4    Tsuge, M.5    Kawakami, Y.6    Aikata, H.7    Abe, H.8    Hayes, C.N.9    Sasaki, T.10
  • 32
    • 84898990930 scopus 로고    scopus 로고
    • New hepatitis C therapies: The toolbox, strategies, and challenges
    • Pawlotsky, J.M. New hepatitis C therapies: The toolbox, strategies, and challenges. Gastroenterology 2014, 146, 1176–1192.
    • (2014) Gastroenterology , vol.146 , pp. 1176-1192
    • Pawlotsky, J.M.1
  • 35
    • 84873604286 scopus 로고    scopus 로고
    • Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
    • Wyles, D.L. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J. Infect. Dis. 2013, 207 (Suppl. 1), S33–S39.
    • (2013) J. Infect. Dis , vol.207 , pp. S33-S39
    • Wyles, D.L.1
  • 38
    • 84883219967 scopus 로고    scopus 로고
    • Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
    • McPhee, F.; Hernandez, D.; Yu, F.; Ueland, J.; Monikowski, A.; Carifa, A.; Falk, P.; Wang, C.; Fridell, R.; Eley, T.; et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 2013, 58, 902–911.
    • (2013) Hepatology , vol.58 , pp. 902-911
    • McPhee, F.1    Hernandez, D.2    Yu, F.3    Ueland, J.4    Monikowski, A.5    Carifa, A.6    Falk, P.7    Wang, C.8    Fridell, R.9    Eley, T.10
  • 39
    • 84898663922 scopus 로고    scopus 로고
    • Daclatasvir plus sofosbuvir for HCV infection
    • Sulkowski, M.S.; Jacobson, I.M.; Nelson, D.R. Daclatasvir plus sofosbuvir for HCV infection. N. Engl. J. Med. 2014, 370, 1560–1561.
    • (2014) N. Engl. J. Med , vol.370 , pp. 1560-1561
    • Sulkowski, M.S.1    Jacobson, I.M.2    Nelson, D.R.3
  • 40
    • 84925362379 scopus 로고    scopus 로고
    • Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS)
    • Bourliere, M.; Bronowicki, J.P.; de Ledinghen, V.; Hezode, C.; Zoulim, F.; Mathurin, P.; Tran, A.; Larrey, D.G.; Ratziu, V.; Alric, L.; et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect. Dis. 2015, 15, 397–404.
    • (2015) Lancet Infect. Dis , vol.15 , pp. 397-404
    • Bourliere, M.1    Bronowicki, J.P.2    De Ledinghen, V.3    Hezode, C.4    Zoulim, F.5    Mathurin, P.6    Tran, A.7    Larrey, D.G.8    Ratziu, V.9    Alric, L.10
  • 41
    • 84925607745 scopus 로고    scopus 로고
    • Virological response after 6 week triple-drug regimens for hepatitis C: A proof-of-concept phase 2A cohort study
    • Kohli, A.; Osinusi, A.; Sims, Z.; Nelson, A.; Meissner, E.G.; Barrett, L.L.; Bon, D.; Marti, M.M.; Silk, R.; Kobt, C.; et al. Virological response after 6 week triple-drug regimens for hepatitis C: A proof-of-concept phase 2A cohort study. Lancet 2015, 385, 1107–1113.
    • (2015) Lancet , vol.385 , pp. 1107-1113
    • Kohli, A.1    Osinusi, A.2    Sims, Z.3    Nelson, A.4    Meissner, E.G.5    Barrett, L.L.6    Bon, D.7    Marti, M.M.8    Silk, R.9    Kobt, C.10
  • 42
    • 84931560807 scopus 로고    scopus 로고
    • Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2015
    • European Association for the Study of the Liver. Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2015. J. Hepatol. 2015, 63, 199–236.
    • (2015) J. Hepatol , vol.63 , pp. 199-236
  • 48
    • 79955060448 scopus 로고    scopus 로고
    • PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus
    • Bzowej, N.; Nelson, D.R.; Terrault, N.A.; Everson, G.T.; Teng, L.L.; Prabhakar, A.; Charlton, M.R. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transplant. 2011, 17, 528–538.
    • (2011) Liver Transplant , vol.17 , pp. 528-538
    • Bzowej, N.1    Nelson, D.R.2    Terrault, N.A.3    Everson, G.T.4    Teng, L.L.5    Prabhakar, A.6    Charlton, M.R.7
  • 49
    • 11844249361 scopus 로고    scopus 로고
    • Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation
    • Shergill, A.K.; Khalili, M.; Straley, S.; Bollinger, K.; Roberts, J.P.; Ascher, N.A.; Terrault, N.A. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am. J. Transplant. 2005, 5, 118–124.
    • (2005) Am. J. Transplant , vol.5 , pp. 118-124
    • Shergill, A.K.1    Khalili, M.2    Straley, S.3    Bollinger, K.4    Roberts, J.P.5    Ascher, N.A.6    Terrault, N.A.7
  • 51
    • 73449143487 scopus 로고    scopus 로고
    • Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation
    • Carrion, J.A.; Torres, F.; Crespo, G.; Miquel, R.; Garcia-Valdecasas, J.C.; Navasa, M.; Forns, X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010, 51, 23–34.
    • (2010) Hepatology , vol.51 , pp. 23-34
    • Carrion, J.A.1    Torres, F.2    Crespo, G.3    Miquel, R.4    Garcia-Valdecasas, J.C.5    Navasa, M.6    Forns, X.7
  • 54
    • 33745343818 scopus 로고    scopus 로고
    • Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: A review and quantitative analysis
    • Wang, C.S.; Ko, H.H.; Yoshida, E.M.; Marra, C.A.; Richardson, K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: A review and quantitative analysis. Am. J. Transplant. 2006, 6, 1586–1599.
    • (2006) Am. J. Transplant , vol.6 , pp. 1586-1599
    • Wang, C.S.1    Ko, H.H.2    Yoshida, E.M.3    Marra, C.A.4    Richardson, K.5
  • 55
    • 52149121573 scopus 로고    scopus 로고
    • Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: Systematic review and meta-analysis of prospective controlled studies
    • Xirouchakis, E.; Triantos, C.; Manousou, P.; Sigalas, A.; Calvaruso, V.; Corbani, A.; Leandro, G.; Patch, D.; Burroughs, A. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: Systematic review and meta-analysis of prospective controlled studies. J. Viral Hepat. 2008, 15, 699–709.
    • (2008) J. Viral Hepat , vol.15 , pp. 699-709
    • Xirouchakis, E.1    Triantos, C.2    Manousou, P.3    Sigalas, A.4    Calvaruso, V.5    Corbani, A.6    Leandro, G.7    Patch, D.8    Burroughs, A.9
  • 56
    • 33745997054 scopus 로고    scopus 로고
    • Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C
    • Berenguer, M.; Palau, A.; Fernandez, A.; Benlloch, S.; Aguilera, V.; Prieto, M.; Rayon, J.M.; Berenguer, J. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transplant. 2006, 12, 1067–1076.
    • (2006) Liver Transplant , vol.12 , pp. 1067-1076
    • Berenguer, M.1    Palau, A.2    Fernandez, A.3    Benlloch, S.4    Aguilera, V.5    Prieto, M.6    Rayon, J.M.7    Berenguer, J.8
  • 58
    • 84936845723 scopus 로고    scopus 로고
    • Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study
    • Poordad, F.; Schiff, E.R.; Vierling, J.M.; Landis, C.; Fontana, R.J.; Yang, R.; McPhee, F.; Hughes, E.A.; Noviello, S.; Swenson, E.S. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study. J. Hepatol. 2015, 62, S261–S262.
    • (2015) J. Hepatol , vol.62 , pp. S261-S262
    • Poordad, F.1    Schiff, E.R.2    Vierling, J.M.3    Landis, C.4    Fontana, R.J.5    Yang, R.6    McPhee, F.7    Hughes, E.A.8    Noviello, S.9    Swenson, E.S.10
  • 59
    • 84936846679 scopus 로고    scopus 로고
    • .. The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort
    • Coilly, A.; Fougerou, C.; de Ledinghen, V.; Houssel-Debry, P.; Duvoux, C.; di Martino, V.; Radenne, S.; Kamar, N.; d'Alteroche, L.; Leroy, V.; et al. The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort. J. Hepatol. 2015, 62, S236–S237.
    • (2015) J. Hepatol , vol.62 , pp. S236-S237
    • Coilly, A.1    Fougerou, C.2    De Ledinghen, V.3    Houssel-Debry, P.4    Duvoux, C.5    Di Martino, V.6    Radenne, S.7    Kamar, N.8    D'alteroche, L.9    Leroy, V.10
  • 60
    • 84928068548 scopus 로고    scopus 로고
    • Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir
    • Badri, P.; Dutta, S.; Coakley, E.; Cohen, D.; Ding, B.; Podsadecki, T.; Bernstein, B.; Awni, W.; Menon, R. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am. J. Transplant. 2015, 15, 1313–1322.
    • (2015) Am. J. Transplant , vol.15 , pp. 1313-1322
    • Badri, P.1    Dutta, S.2    Coakley, E.3    Cohen, D.4    Ding, B.5    Podsadecki, T.6    Bernstein, B.7    Awni, W.8    Menon, R.9
  • 61
    • 84939653819 scopus 로고    scopus 로고
    • Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus
    • AASLD/IDSA HCV Guidance Panel. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus. Hepatology 2015, 62, 932–954.
    • (2015) Hepatology , vol.62 , pp. 932-954
  • 63
    • 84942437304 scopus 로고    scopus 로고
    • online, (accessed on 1 June 2015)
    • University of Liverpool. Hep-Druginteractions [online]. 2015. Available online: www.hep-druginteractions.org (accessed on 1 June 2015).
    • (2015) Hep-Druginteractions
  • 65
    • 84942413675 scopus 로고    scopus 로고
    • The pharmacokinetics of Ledipasvir, an HCV specific NS5A inhibitor in HCV-uninfected subjects with moderate and severe hepatic impairement
    • German-Polina, A.M.; Yang, J.C.; McNair, L.; Shen, G. The pharmacokinetics of Ledipasvir, an HCV specific NS5A inhibitor in HCV-uninfected subjects with moderate and severe hepatic impairement. Hepatology 2013.
    • (2013) Hepatology
    • German-Polina, A.M.1    Yang, J.C.2    McNair, L.3    Shen, G.4
  • 67
    • 84899736863 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of co-administered ABT-450 plus ritonavir (ABT 450/r), ABT 267, and ABT 333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate and severe hepatic impairment
    • Khatri, A.; Gaultier, I.A.; Menon, R.; Marbury, T.C.; Lawitz, E.; Podsadecki, T.J.; Mullally, V.; Awni, W.M.; Bernstein, B.; Dutta, S. Pharmacokinetics and safety of co-administered ABT-450 plus ritonavir (ABT 450/r), ABT 267, and ABT 333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate and severe hepatic impairment. Hepatology 2012.
    • (2012) Hepatology
    • Khatri, A.1    Gaultier, I.A.2    Menon, R.3    Marbury, T.C.4    Lawitz, E.5    Podsadecki, T.J.6    Mullally, V.7    Awni, W.M.8    Bernstein, B.9    Dutta, S.10
  • 69
    • 84856044809 scopus 로고    scopus 로고
    • Education by a nurse increases the adherence to therapy in chronic hepatitis C patients
    • Alavian, S.M.; Aalaei-Andabili, S.H. Education by a nurse increases the adherence to therapy in chronic hepatitis C patients. Clin. Gastroenterol. Hepatol. 2012, 10, 203.
    • (2012) Clin. Gastroenterol. Hepatol , vol.10
    • Alavian, S.M.1    Aalaei-Andabili, S.H.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.